CLINICAL TRIALS AND OBSERVATIONS Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMAWorking Party on CML analysis
نویسندگان
چکیده
*Simona Luatti,1 *Fausto Castagnetti,1 Giulia Marzocchi,1 Carmen Baldazzi,1 Gabriele Gugliotta,1 Ilaria Iacobucci,1 Giorgina Specchia,2 Lucia Zanatta,3 Giovanna Rege-Cambrin,4 Marco Mancini,5 Elisabetta Abruzzese,6 Alfonso Zaccaria,7 Maria Grazia Grimoldi,8 Alessandro Gozzetti,9 Gaia Ameli,1 Maria Adele Capucci,10 Giandomenico Palka,11 Paolo Bernasconi,12 Francesca Palandri,1 Fabrizio Pane,13 Giuseppe Saglio,4 Giovanni Martinelli,1 Gianantonio Rosti,1 Michele Baccarani,1 and Nicoletta Testoni,1 on behalf of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Working Party on CML
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMAWorking Party on CML analysis
Giulia Marzocchi,1 Fausto Castagnetti,1 Simona Luatti,1 Carmen Baldazzi,1 Monica Stacchini,1 Gabriele Gugliotta,1 Marilina Amabile,1 Giorgina Specchia,2 Mario Sessarego,3 Ursula Giussani,4 Laura Valori,5 Giancarlo Discepoli,6 Anna Montaldi,7 Alessandra Santoro,8 Laura Bonaldi,9 Giovanni Giudici,10 Anna Maria Cianciulli,11 Francesca Giacobbi,12 Francesca Palandri,1 Fabrizio Pane,13 Giuseppe Sagl...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-
Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronicphase CML after failure on interferonwere treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 mon...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase
In chronic myelogenous leukemia (CML) imatinib mesylate has been shown to selectively inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent alone high rates of cytogenetic responses were recorded. However, several mechanisms of resistance have been described. In vitro studies examining the effects of imatinib mesylate plus cytarabine have shown synergistic...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. Large deletions on the derivative chromosome 9 have recently been reported, but it was unclear whether deletions arose during disease progression or at the time of the Ph translocation. Fluorescence in situ hybridi...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase
The relative merits of allogeneic hematopoietic stem cell transplantation (alloHSCT) and imatinib for chronic myelogenous leukemia in the accelerated phase (AP-CML) have not previously been evaluated. This cohort study was designed to compare the outcomes of imatinib (n 87) versus allo-HSCT (n 45) for AP-CML. A multivariate analysis of the total population revealed that a CML duration > 12 mont...
متن کامل